DERMATA THERAPEUTICS
Dermata is a development-stage biotechnology company that focuses on making major advancements in the treatment of serious diseases treated by dermatologists. Its business strategy is to identify and develop innovative products that move into clinical trials to demonstrate efficacy and safety in a variety of diseases. They currently exploring the use of a unique botanical product with multiple proposed mechanisms of action in order to treat acne. It was founded in 2014 and headquartered in Encinitas, California.
DERMATA THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2014-01-01
Address:
Encinitas, California, United States
Country:
United States
Website Url:
http://www.dermatarx.com
Total Employee:
1+
Status:
Active
Contact:
858-756-2480
Total Funding:
20.56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Apache Euro Microsoft Exchange Online Amazon
Current Employees Featured
David Hale Co-Founder and Managing Director @ Dermata Therapeutics
Co-Founder and Managing Director
Gerald Proehl Founder, President, CEO & Director @ Dermata Therapeutics
Founder, President, CEO & Director
Gerald Proehl President, CEO and Managing Director @ Dermata Therapeutics
President, CEO and Managing Director
Founder
Stock Details
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Dermata Therapeutics
Official Site Inspections
http://www.dermatarx.com Semrush global rank: 5.57 M Semrush visits lastest month: 1.52 K
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Dermata Therapeutics"
About Us - Dermata
He previously served on the boards of Biotechnology Innovation Organization, BIO Emerging Companies Section Governing Board, BIO Health Section Governing Board, and Sangamo …See details»
Dermata
Dermata is a clinical-stage biotechnology company founded in late 2014 focused on the treatment of multiple medical and aesthetic skin conditions and diseases with high unmet needs.See details»
Board Committees :: Dermata Therapeutics, Inc. (DRMA)
From 1997 to 2005, Dr. Mento was President, Chief Executive Officer and a member of the board of directors of Idun Pharmaceuticals, Inc. Dr. Mento guided Idun during its transition from a …See details»
Corporate Governance :: Dermata Therapeutics, Inc. (DRMA)
Steven J. Mento, Ph.D. serves as a director on the board of directors of Conatus Pharmaceuticals Inc. since 2005, and from 2005 to 2012, Dr. Mento served as chairman of Conatus’ board of …See details»
Management Team :: Dermata Therapeutics, Inc. (DRMA)
Kyri Van Hoose is a seasoned and collaborative finance and accounting professional with over 20 years of experience, including more than 15 years of experience in the life science industry. Ms. Van Hoose joined Dermata …See details»
Company Information :: Dermata Therapeutics, Inc. (DRMA)
Company Contact Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd. #322 San Diego, CA 92130See details»
Company — Dermata
Our diverse and experienced leadership team has spent many years developing and commercializing pharmaceutical products in the US and throughout the world.See details»
Dermata Therapeutics - Crunchbase Company Profile & Funding
Contact Email info@dermatarx.com Phone Number 858-756-2480 Dermata is a development-stage biotechnology company that focuses on making major advancements in the treatment of …See details»
Dermata Therapeutics - Overview, News & Similar companies
Explore Complete Organization Structure. Is Dermata Therapeutics your ideal customer? Let us give you the heads up on whether it's a good time to reach out ... (858) 800-2543 Website: …See details»
Dermata Therapeutics | MedPath
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the …See details»
Dermata Therapeutics, Inc. (DRMA) - Yahoo Finance
See the company profile for Dermata Therapeutics, Inc. (DRMA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Dermata Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Investors: Cliff Mastricola Investor Relations cmastricola@dermatarx.com SOURCE: Dermata Therapeutics Released January 22, 2025. ... The statistics for drugs in the Pipeline is the …See details»
Dermata 2025 Company Profile: Stock Performance & Earnings
Dermata General Information Description. Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing …See details»
Investor Relations :: Dermata Therapeutics, Inc. (DRMA)
Mar 17, 2025 We are a clinical-stage biotechnology company founded in 2014 focused on developing and commercializing products for the treatment of various skin disease and …See details»
Contact - Dermata
We are also looking to for strategic partners for development of DMT410. If you possess a product which fits one of our core areas of focus, dermatology or ophthalmology, or are interested in …See details»
Dermata Therapeutics, Inc. (Dermata Therapeutics, Inc.) - 药物管 …
May 1, 2023 - STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI™ Phase 3 STAR-1 trial …See details»
Dermata Therapeutics Provides Corporate Update and Reports …
Mar 17, 2025 Investors: Cliff Mastricola Investor Relations cmastricola@dermatarx.com. SOURCE: Dermata Therapeutics View the original press release on ACCESS Newswire. …See details»
Dermata Therapeutics Announces Closing of $2.55 Million
Jan 23, 2025 SAN DIEGO, CA/ ACCESS Newswire/ January 23, 2025/ Dermata Therapeutics, Inc., a late-stage biotechnology company focused on the treatment of medical and aesthetic …See details»
Dermata Therapeutics Provides Corporate Update and Reports …
Nov 13, 2024 Dermata Therapeutics, Inc., a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent …See details»
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets …
2 hours ago - XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once …See details»